About Dyax (NASDAQ:DYAX)
Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-14.86%
Return on Assets-12.09%
Dyax (NASDAQ:DYAX) Frequently Asked Questions
What is Dyax's stock symbol?
Dyax trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax's earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) announced its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analysts' expectations of $24.96 million. Dyax had a negative net margin of 47.32% and a negative return on equity of 14.86%. The business's revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned ($0.01) earnings per share. View Dyax's Earnings History.
Who are some of Dyax's key competitors?
Some companies that are related to Dyax include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Medivation (MDVN), Kite Pharma (KITE), bluebird bio (BLUE), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Bioverativ (BIVV), Juno Therapeutics (JUNO), Shire-Nps Pharmaceuticals (NPSP), Beigene (BGNE), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Sarepta Therapeutics (SRPT), Auspex Pharmaceuticals (ASPX), AveXis (AVXS) and Clovis Oncology (CLVS).
How do I buy Dyax stock?
Shares of Dyax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyax's stock price today?
One share of Dyax stock can currently be purchased for approximately $38.41.
How can I contact Dyax?
Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.
MarketBeat Community Rating for Dyax (DYAX)MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dyax (NASDAQ:DYAX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Dyax (NASDAQ:DYAX) Earnings History and Estimates Chart
Dyax (NASDAQ DYAX) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/28/2015||Q315||($0.08)||($0.08)||$24.96 million||$24.70 million||View||N/A|
|7/29/2015||Q215||($0.04)||($0.06)||$23.40 million||$264.00 million||View||Listen|
|4/29/2015||Q115||($0.05)||($0.05)||$21.79 million||$20.40 million||View||N/A|
|2/24/2015||Q414||($0.04)||($0.02)||$19.90 million||$26.00 million||View||N/A|
|10/28/2014||Q314||($0.06)||($0.01)||$15.70 million||$22.00 million||View||N/A|
|7/29/2014||Q214||($0.05)||($0.02)||$14.13 million||$19.59 million||View||N/A|
|4/30/2014||Q1 2014||($0.05)||($0.05)||$13.65 million||$14.12 million||View||N/A|
|2/28/2014||Q413||($0.04)||($0.02)||$15.84 million||$16.90 million||View||N/A|
Dyax (NASDAQ:DYAX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Dyax (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com
Dyax (NASDAQ DYAX) Insider Trading and Institutional Ownership History
Dyax (NASDAQ DYAX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/10/2015||Thomas L Kempner||Director||Sell||6,000||$22.47||$134,820.00|| |
|8/28/2015||Thomas L Kempner||Director||Sell||17,947||$23.83||$427,677.01|| |
|8/18/2015||Thomas L Kempner||Director||Sell||18,035||$23.83||$429,774.05|| |
|8/13/2015||Thomas L Kempner||Director||Sell||4,848||$23.81||$115,430.88|| |
|7/20/2015||Henry E Blair||Director||Sell||50,000||$27.05||$1,352,500.00|| |
|6/8/2015||David J Mclachlan||Director||Sell||75,000||$25.63||$1,922,250.00|| |
|3/6/2015||Andrew D Ashe||EVP||Sell||2,400||$15.50||$37,200.00|| |
|3/5/2015||Burt A Adelman||CMO||Sell||9,375||$15.66||$146,812.50|| |
|3/5/2015||George V Migausky||CFO||Sell||5,000||$15.86||$79,300.00|| |
|3/5/2015||Gustav Christensen||CEO||Sell||6,250||$15.86||$99,125.00|| |
|2/26/2015||Andrew D Ashe||EVP||Sell||1,500||$15.34||$23,010.00|| |
|1/2/2015||Burt A Adelman||CMO||Sell||75,000||$14.05||$1,053,750.00|| |
|12/5/2014||Thomas L Kempner||Director||Sell||14,764||$13.79||$203,595.56|| |
|11/21/2014||Thomas L Kempner||Director||Sell||100,000||$13.20||$1,320,000.00|| |
|9/12/2014||Thomas L Kempner||Director||Sell||12,400||$11.00||$136,400.00|| |
|8/26/2014||Thomas L Kempner||Director||Sell||37,000||$10.39||$384,430.00|| |
|8/19/2014||Thomas L Kempner||Director||Sell||113,755||$9.67||$1,100,010.85|| |
|8/7/2014||Thomas L Kempner||Director||Sell||33,190||$9.25||$307,007.50|| |
|6/13/2014||George V Migausky||CFO||Sell||16,000||$8.26||$132,160.00|| |
|3/5/2014||Henry Blair||Director||Sell||150,000||$10.46||$1,569,000.00|| |
|3/3/2014||Andrew Ashe||EVP||Sell||30,000||$10.00||$300,000.00|| |
|3/3/2014||Burt Adelman||CMO||Sell||55,000||$9.68||$532,400.00|| |
|2/26/2014||Andrew Ashe||VP||Sell||2,723||$10.10||$27,502.30|| |
|12/5/2013||Thomas Kempner||Director||Sell||400,000||$8.37||$3,348,000.00|| |
|8/13/2013||Andrew Ashe||VP||Sell||32,500||$4.30||$139,750.00|| |
|5/16/2013||Marc D Kozin||Director||Buy||22,971||$2.46||$56,508.66|| |
|2/25/2013||George V Migausky||CFO||Sell||4,275||$3.28||$14,022.00|| |
|2/25/2013||Ivana Magovcevic||COO||Sell||4,015||$3.24||$13,008.60|| |
Dyax (NASDAQ DYAX) News Headlines
Dyax (NASDAQ:DYAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dyax (NASDAQ:DYAX) Income Statement, Balance Sheet and Cash Flow Statement
Dyax (NASDAQ DYAX) Stock Chart for Sunday, December, 17, 2017